Additionally, survival analysis revealed that patients with low PLK4 expression had a significantly higher 5-year overall survival (OS) and progression-free survival (PFS) rate compared to those with high PLK4 expression, which demonstrated a crucial role for PLK4 in CRC progression (Figure 3D). Here, PLK4 is linked to colorectal carcinoma.